HIV decision support: from molecule to man

@article{Sloot2009HIVDS,
  title={HIV decision support: from molecule to man},
  author={Peter M. A. Sloot and Peter V. Coveney and G{\"o}khan Ertaylan and Viktor M{\"u}ller and Charles Ab Boucher and Marian Bubak},
  journal={Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences},
  year={2009},
  volume={367},
  pages={2691 - 2703}
}
  • P. Sloot, P. Coveney, M. Bubak
  • Published 13 July 2009
  • Biology
  • Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences
Human immunodeficiency virus (HIV) is recognized to be one of the most destructive pandemics in recorded history. Effective highly active antiretroviral therapy and the availability of genetic screening of patient virus data have led to sustained viral suppression and higher life expectancy in patients who have been infected with HIV. The sheer complexity of the disease stems from the multiscale and highly dynamic nature of the system under study. The complete cascade from genome, proteome… 
Modeling and Simulation of HIV-1 Intracellular Replication
TLDR
The model is basically designed to study HIV replication inside a single cell before initiation of drug therapy and gives insights about the detail of HIV replication dynamics inside the cell at protein level and can be used for future studies of HIV intracellular replication in vivo and drug treatment.
Patient‐Specific Modelling in Drug Design, Development and Selection Including its Role in Clinical Decision‐Making
TLDR
It is shown here using case studies in cancer and HIV how such computational models, and particularly models based on individual patient data, can be used for drug design and development, and in the selection of the appropriate treatment for a given patient in the face of resistance mutations.
Towards Personalised Drug Ranking in Clinical Decision Support
TLDR
The findings demonstrate the potential for molecular simulations to achieve an accurate ranking of drug binding affinities on clinically relevant time scales and represent the first steps towards the eventual goal of providing data derived from patient specific simulation to enhance clinical decision support systems.
A logical framework for detecting anomalies in drug resistance algorithms
TLDR
The final aim is reasoning on the properties of algorithm modeling the interaction among drugs and HIV virus and detecting its anomalies such as rules that can never be satisfied and subset of rules that are in contradiction.
Exploring the Relationship between Adherence to Treatment and Viral Load through a New Discrete Simulation Model of HIV Infectivity
TLDR
It is found that a small lack of adherence could have a proportionally much larger impact on infection as well as trigger negative effects on health sooner, and small issues in adherence should be addressed early on.
Molecular dynamics simulation of drug resistance in HIV-1 protease and reverse transcriptase
TLDR
It is demonstrated that ensemble simulations exhibit significantly enhanced thermodynamic sampling over single long simulations and the effects on drug binding of the mutations at positions 10, 71 and 90 appear to be highly dependent on the background mutations present in the remainder of the sequence.
Resolution of Discordant HIV-1 Protease Resistance Rankings Using Molecular Dynamics Simulations
TLDR
Changes in the relative conformation of the two beta sheets that form the protease dimer interface are identified which suggest an explanation of the relative frequency of different amino acids observed in patients at residue 71 and are identified in ensemble molecular dynamics simulations.
UvA-DARE ( Digital Academic Repository ) Identifying potential survival strategies of HIV-1 through virus-host protein interaction networks
TLDR
HIV infection results in a reprioritization of cellular processes reflected by an increase in the relative importance of transcriptional machinery and proteasome formation, resulting in a system where virus proteins preferably interact with central human proteins for direct control and with proteasomal proteins for indirect control over the cellular processes.
From base pair to bedside: molecular simulation and the translation of genomics to personalized medicine
TLDR
The use of molecular modeling to generate quantitative and qualitative insights at the smallest scales of the systems biology hierarchy is discussed, how it can play an important role in the development of a systems understanding of disease and in the application of such knowledge to help discover new therapies and target existing ones on a personal level.
articleIdentifying potential survival strategies of HIV-1 through virus-host protein interaction networks
TLDR
HIV infection results in a reprioritization of cellular processes reflected by an increase in the relative importance of transcriptional machinery and proteasome formation, resulting in a system where virus proteins preferably interact with central human proteins for direct control and with proteasomal proteins for indirect control over the cellular processes.
...
...

References

SHOWING 1-10 OF 33 REFERENCES
Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors.
  • K. Deforche, R. Camacho, A. Vandamme
  • Biology
    Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases
  • 2007
A new cell-based assay for measuring the forward mutation rate of HIV-1.
Life expectancy of patients with newly-diagnosed HIV infection in the era of highly active antiretroviral therapy.
TLDR
The results support the expansion of HIV screening programs to minimize delay in diagnosis and raise questions about what kind of preventive heath services should be offered.
Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase
TLDR
In vivo mutation rates for HIV-1 are three and seven times higher than those previously reported for two other retroviruses, spleen necrosis virus and bovine leukemia virus, respectively, and the calculated in vivo mutation rate is about 20-fold lower than the error rate of purified HIV- 1 reverse transcriptase, with the same target sequence.
Estimation of an in vivo fitness landscape experienced by HIV-1 under drug selective pressure useful for prediction of drug resistance evolution during treatment
TLDR
A method to estimate this fitness landscape from cross-sectional clinical genetic sequence data of different subtypes, by reverse engineering the required selective pressure for HIV-1 sequences obtained from treatment naive patients, to evolve towards Sequence obtained from treated patients is proposed.
Physician Experience in the Care of HIV‐Infected Persons Is Associated With Earlier Adoption of New Antiretroviral Therapy
TLDR
Greater physician experience in the care of persons with HIV infection is associated with earlier adoption and appropriate use of new antiretroviral treatment regimens regardless of whether physicians practice in a rural or urban area.
Human Immunodeficiency Virus
Mutations in the human immunodeficiency virus (HIV) protease (L90M, G48V, and L90M/G48V) arise when HIV is passaged in the presence of the HIV protease inhibitor saquinavir. These mutations yield a
Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance in vivo.
TLDR
The correlations suggest that the population ratio of the protease species is driven by in vivo saquinavir concentration, which appears to be in the range 10(-10)-10(-9) M during the clinical trials.
Cellular Automata Model of Drug Therapy for HIV Infection
TLDR
A non-uniform CA model is developed to study the dynamics of drug therapy of HIV infection, which simulates four- phases (acute, chronic, drug treatment responds and onset of AIDS); results indicate that both simulations (with and without treatments) evolve to the relatively same steady state.
From molecule to man: Decision support in individualized E-health
TLDR
ViroLab, a grid-based decision-support system, demonstrates how researchers can now study diseases from the DNA level all the way up to medical responses to treatment.
...
...